Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool January 28, 2010 Brian Orelli	The Biggest Development-Stage Drugmaker, Ever Eli Lilly seems to have a lot more in common with its development-stage little brothers than it does with its big pharma brethren.
The Motley Fool March 23, 2011 Brian Orelli	Eli Lilly: Great Plan, Poor Execution Eli Lilly shuns large mergers, but hasn't produced drugs on its own.
The Motley Fool May 24, 2011 Brian Orelli	If at First You Don't Succeed, Spin It Off Eli Lilly ditches Xigris by spinning off BioCritica.
The Motley Fool August 4, 2010 Ryan McBride	How Eli Lilly Let a Billion-Dollar Molecule Slip Away, and Make a Fortune for Vertex The remains of Lilly's partnership with Vertex Pharmaceuticals.
The Motley Fool November 26, 2010 Brian Orelli	Black Friday Biotech Bargains Drugmakers on sale.
The Motley Fool October 7, 2008 Brian Orelli	Eli Lilly's Risky Gamble Eli Lilly is desperate, and the high acquisition price of ImClone shows it.
The Motley Fool December 14, 2010 Brian Orelli	Another Mishap for a Drugmaker That Can't Afford It Eli Lilly puts cancer drug tasisulam on a clinical hold.
The Motley Fool July 23, 2010 Brian Orelli	Eli Lilly Looks Great Today, but I'm Concerned About Tomorrow Eli Lilly is firing on all cylinders, but is there a blowout in its future?
The Motley Fool May 18, 2010 Brian Orelli	What Astellas' Purchase of OSI Means for Biotech Investors Stop buying for the potential takeout.
The Motley Fool June 30, 2010 Rich Smith	This Just In: Upgrades and Downgrades Major Wall Street investment house Soleil Securities downgraded Eli Lilly shares to "sell."
The Motley Fool August 17, 2007 Brian Lawler	The Perfect Pharma Acquisition The pharmaceutical industry has been busy consolidating in the past year. With so much buying and selling going on, here is speculation on what would constitute the perfect pharma acquisition.
The Motley Fool January 22, 2007 Brian Lawler	Adios, ICOS The pharmaceutical gets finally consumed by Eli Lilly. The deal offered a nice premium to ICOS shareholders. At the same time, it was a good deal for Lilly.
The Motley Fool October 22, 2007 Brian Lawler	Modest Numbers From Eli Lilly Its sales were up for the quarter, but a new drug might be the best indicator of its prospects. Lilly's pipeline will dictate its near-term future.
The Motley Fool December 31, 2010 Brian Orelli	How the Other Half of Pharma Lives A dive into spec pharma.
The Motley Fool July 6, 2009 Brian Orelli	Lilly Shows Us How It's Done The company announces that the Food and Drug Administration had expanded the approval of its cancer drug, Alimta, to include maintenance therapy for nonsquamous, non-small cell lung cancer.
The Motley Fool November 24, 2010 Brian Orelli	A Manly FDA Approval Eli Lilly has something to be thankful for this week; the Food and Drug Administration approved Axiron, its testosterone replacement therapy.
The Motley Fool October 21, 2010 Brian Orelli	Nice Earnings, Eli Lilly, but ... Eli Lilly trounced analysts' earnings estimates today, but investors sighed -- and for good reason.
The Motley Fool June 25, 2008 Brian Lawler	Why the Lilly Delay, FDA? A government review of the company's top drug candidate gets pushed back.
The Motley Fool November 26, 2007 Brian Lawler	Glaxo Goes Holiday Shopping The pharmaceutical giant snaps up another acquisition, privately held Reliant Pharmaceuticals, for $1.65 billion in cash, one of the largest pharma deals of the year.
The Motley Fool August 29, 2008 Brian Lawler	Will Biopharma Acquisitions Never Cease? In both the size and quantity of proposed deals, the past 24 months have been busier than ever for biopharma dealmakers. What's behind all this activity?
The Motley Fool January 26, 2005 Stephen D. Simpson	Lilly's No Wallflower The drugmaker posts tepid results as it bides time before new products hit the market. Lilly's valuation suggests that Wall Street has faith that those new drugs will come through.
The Motley Fool March 30, 2010 Brian Orelli	Invest in This Space at Your Own Risk Lung cancer is a tough foe for drugmakers.
The Motley Fool March 31, 2008 Brian Lawler	SGX Down for the Count? The pharmaceutical's lead drug fares poorly in clinical testing.
The Motley Fool August 13, 2010 Brian Orelli	Already a Slippery Slope for Eli Lilly The company gets a whiff of what its patent cliff might be like.
The Motley Fool January 30, 2008 Brian Lawler	Eli Lilly Is Resilient Proving that not every sector is affected by downturns, Eli Lilly released its fourth-quarter results yesterday, showing a bit of top-line growth.
The Motley Fool August 31, 2007 Brian Lawler	4 Biotech Bets Under $10 Development stage drugmakers are among the most exciting stocks to follow. Here are four that are all worth a place on your watch list: Pharmacopeia, Pain Therapeutics, Pharmasset, and SGX Pharmaceuticals.
The Motley Fool January 27, 2011 Rich Smith	What's Behind the Run-Up at Rexahn? The pharmaceutical's hot streak could soon burn up all its cash.
The Motley Fool April 22, 2011 Sean Williams	Pharma's Most Perilous Pipelines Patent expirations expose weaknesses for these Wall Street darlings.
The Motley Fool October 20, 2006 Brian Lawler	Lilly Pads Its Earnings Lilly reports third-quarter 2006 numbers and gobbles up Cialis. Investors, take note.
The Motley Fool January 12, 2011 Brian Orelli	Drugmaker Math: 4 Halves Beat 2 Wholes Eli Lilly and Boehringer Ingelheim hook up.
The Motley Fool December 29, 2006 Brian Lawler	Lilly's Patents Stay in Bloom Even with upcoming patent expiries, Lilly isn't in nearly the same desperate situation that some of its large-cap pharma peers will be dealing with in the upcoming years. Investors, take note.
The Motley Fool October 17, 2006 Brian Lawler	Lilly Doesn't Like Sharing Profits The company is buying out ICOS Corporation, its partner in erectile-dysfunction drug Cialis. Investors, take note.
The Motley Fool December 21, 2010 Brian Orelli	4 Drugmakers, 5 Deals, Christmas Is Here It looks like there were a lot of people in the business development offices at pharmaceutical companies looking to get their work done before taking off for the holidays. Check out all the deals that were announced yesterday.
The Motley Fool March 27, 2008 Brian Lawler	Eli Lilly Hands Over Cold Cash Lilly loses to the state of Alaska in a courtroom battle over its top drug Zyprexa.
The Motley Fool June 6, 2011 Brian Orelli	Big Pharma Tackles Lung Cancer; Biotech Helping, Too A big underserved market.
The Motley Fool December 12, 2008 Brian Orelli	A Long-Term Play for Your Port Long-term prospects look better than the near term ones for Eli Lilly and its investors.
The Motley Fool May 31, 2007 Ryan Fuhrmann	Dueling Fools: Eli Lilly Bull Thanks to a couple of recent developments and a focus on research & development, the pharma giant is a worthy contender for health-care exposure in investors' portfolios.
BusinessWeek February 25, 2010 Weintraub & Tirrell	Eli Lilly's Drug Assembly Line Faced with expiring patents that could weaken sales, Lilly is reorganizing for speed.
The Motley Fool January 28, 2010 Brian Orelli	How to Make a Billion Bucks in Biotech Drug companies and investors alike have to balance the risk and reward.
The Motley Fool May 1, 2007 Brian Lawler	Cardiome Plays Dealmaker Cardiome signs a deal to develop one of Eli Lilly's drug candidates. Investors, take note.
The Motley Fool January 10, 2008 Brian Orelli	Good News for Lucky Men Eli Lilly's erectile dysfunction drug can now be taken daily.
The Motley Fool May 16, 2011 Brian Orelli	Diabetes Drug Duo Duels It Out in Court Amylin sticks up to partner Eli Lilly.
The Motley Fool May 31, 2007 Brian Lawler	Dueling Fools: Eli Lilly Bear Well-managed companies don't always make for good investments. This pharmaceutical powerhouse is a good example.
The Motley Fool October 24, 2008 Brian Orelli	Lilly's Results Run the Gamut The company's GAAP EPS and adjusted EPS are at polar extremes.
The Motley Fool January 26, 2009 Brian Orelli	Which One of These Is Not Like the Other? Bristol-Myers and Eli Lilly run into some comparability issues.
The Motley Fool July 26, 2007 Brian Lawler	Lilly Doesn't Wilt The second quarter was another good one for Eli Lilly. Top-line and bottom-line both grew.
The Motley Fool May 19, 2010 Brian Orelli	The Biggest-Little Biotechs in the World If you do decide to invest in these biotechs before they've secured phase 3 results make sure you know what you're getting yourself into and aren't blindly following the crowd.
BusinessWeek March 20, 2006 Gene G. Marcial	Lilly Is Starting To Bloom Big pharma has been in the doldrums for years, ravaged by generic rivals, class actions, and trickling product pipelines. But some pockets are perking up.
The Motley Fool May 31, 2007 Brian Lawler	Dueling Fools: Eli Lilly Bear Rebuttal Shareholders who buy into Lilly at its current valuation just won't have the same opportunity for stock price appreciation as those who bought shares in the late '80s or early '90s.
The Motley Fool April 19, 2011 Brian Orelli	See You on the Other Side of the Cliff Lilly beats, but there's still a lot of unknowns. Can the company continue the trend through the patent cliff?